SCHEMBL4907053

SCHEMBL4907053

CCN(c1ccc(OCc2c(F)cccc2Cl)cc1)S(=O)(=O)c1cc(C)c(C)c(C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
TSHR P16473 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
ESR1 P03372 1/20 0.39
OXTR P30559 1/20 0.39
AVPR1A P37288 1/20 0.39
KMT2A Q03164 1/20 0.38
ALKBH1 Q13686 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906802 0.92 POLB (0.44) LMNATSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL4895965 0.90 LMNA (0.53) LMNATSHRALDH1A1HPGDALOX15
SCHEMBL4905829 0.87 LMNA (0.53) LMNATSHRALDH1A1HPGDALOX15
SCHEMBL4907012 0.86 LMNA (0.49) LMNATSHRALDH1A1HPGDALOX15
SCHEMBL4905839 0.84 LMNA (0.45) LMNATSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL4906496 0.82 LMNA (0.51) LMNATSHRALDH1A1HPGDALOX15
SCHEMBL4897627 0.82 KEAP1 (0.48) LMNATSHRHSD17B10KMT2A
SCHEMBL4894515 0.82 LMNA (0.45) LMNATSHRALDH1A1HPGDALOX15
SCHEMBL4906732 0.82 LMNA (0.47) LMNATSHRALDH1A1HPGDALOX15
SCHEMBL4911815 0.81 LMNA (0.52) LMNAALDH1A1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD LMNA 317/4885TSHR 412/4885ALDH1A1 2664/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885TSHR 400/4885ALDH1A1 2956/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LMNA 319/4885TSHR 400/4885ALDH1A1 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.